Capital International Ltd. CA Acquires 4,497 Shares of Eli Lilly and Company $LLY

Capital International Ltd. CA grew its holdings in Eli Lilly and Company (NYSE:LLY) by 6.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 73,237 shares of the company’s stock after purchasing an additional 4,497 shares during the period. Eli Lilly and Company comprises 2.8% of Capital International Ltd. CA’s portfolio, making the stock its 6th largest holding. Capital International Ltd. CA’s holdings in Eli Lilly and Company were worth $78,706,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in LLY. Norges Bank acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $12,976,634,000. Capital Research Global Investors increased its holdings in shares of Eli Lilly and Company by 20.9% in the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after purchasing an additional 4,332,008 shares during the period. Vanguard Group Inc. increased its holdings in shares of Eli Lilly and Company by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock valued at $88,087,193,000 after purchasing an additional 1,006,885 shares during the period. Amundi increased its holdings in shares of Eli Lilly and Company by 27.1% in the 3rd quarter. Amundi now owns 4,525,902 shares of the company’s stock valued at $3,823,977,000 after purchasing an additional 964,675 shares during the period. Finally, Jennison Associates LLC increased its holdings in shares of Eli Lilly and Company by 22.3% in the 4th quarter. Jennison Associates LLC now owns 5,133,676 shares of the company’s stock valued at $5,517,059,000 after purchasing an additional 937,204 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on LLY shares. Royal Bank Of Canada reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Thursday, May 21st. The Goldman Sachs Group reiterated a “buy” rating and issued a $1,283.00 target price on shares of Eli Lilly and Company in a report on Friday, May 22nd. Cantor Fitzgerald boosted their price target on Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the company an “overweight” rating in a research note on Friday, May 1st. Leerink Partners set a $1,119.00 price target on Eli Lilly and Company in a research note on Tuesday, May 26th. Finally, Wolfe Research reissued an “outperform” rating and issued a $1,350.00 price target on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $1,227.00.

Eli Lilly and Company Trading Up 0.7%

Shares of NYSE LLY opened at $1,133.15 on Friday. The stock has a market cap of $1.07 trillion, a price-to-earnings ratio of 40.25, a PEG ratio of 1.24 and a beta of 0.53. The business has a 50 day simple moving average of $974.59 and a 200 day simple moving average of $1,013.04. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,166.29. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, research analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Caremark reversed its earlier exclusion and will now cover Eli Lilly’s Zepbound, a meaningful reimbursement win that could expand patient access and bolster obesity-drug sales. Article Title
• Positive Sentiment: WeightWatchers Med+ is now available through LillyDirect, reinforcing Lilly’s distribution ecosystem and strengthening its leadership in chronic weight management. Article Title
• Positive Sentiment: Lilly announced a new Phase 2b obesity trial for macupatide–eloralintide, adding another potential growth driver to its weight-loss pipeline beyond current GLP-1 products. Article Title
• Positive Sentiment: Jim Cramer highlighted Lilly as a potential winner against competitors, with attention on its new pill version of its weight-loss drug and broader competitive advantages. Article Title
• Positive Sentiment: Analysts and market commentary continue to frame LLY as a long-term winner, citing strong execution, deal-making, and diversification efforts beyond obesity drugs. Article Title
• Neutral Sentiment: Lilly also received coverage around its Phase 3 Libretto-432 cancer study and a $1.9 billion Ascidian partnership, both of which support the pipeline but are longer-term in nature. Article Title
• Neutral Sentiment: Broader health-care sector commentary and stock-screen articles were generally supportive, but they are less likely to be a direct driver of LLY’s move than the CVS and pipeline news. Article Title

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.